RICHMOND, Va., May 23, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the Company's shares on Nasdaq , members of Indivior's senior leadership team will be hosting an analyst teach-in event today in New York City. The event, which will be webcast (see details below), is intended to provide an in-depth overview of Indivior's growth and value creation path. During the event, the Company will ...

Indivior PLC (NASDAQ:INDV) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Jason Thompson - VP, IR Mark Crossley - CEO Christian Heidbreder - Chief Scientific Officer Ryan Preblick - CFO Conference Call Participants James Vane-Tempest - Jefferies Max Herrmann - Stifel Chase Knickerbocker - Craig-Hallum Thibault Boutherin - Morgan Stanley Karl Burns - Northland Capital Markets Max Herrmann - Stifel Operator Good day, and thank you for standing by. Welcome to the Indivior PLC Q ...

April 25, 2024 Delivered Double-Digit Net Revenue Growth in Q1 2024; FY 2024 Guidance Reconfirmed Comment by Mark Crossley, CEO of Indivior PLC "Our first quarter results reflect continued double-digit top-line momentum led by SUBLOCADE (buprenorphine extended-release). The underlying demand for this transformative treatment for moderate-to-severe opioid use disorder (OUD) remains strong and our strategy to expand prescribing in the justice system is delivering excellent results. SUBLOCADE's reported growth ...

Indivior PLC (INDV) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.63%. A quarter ago, it was expected that this company would post earnings of $0.28 per share when it actually produced earnings of $0.43, delivering a surprise of 53.57%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Q4 / FY 2023 Results | February 22, 2024 This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, statements regarding the Indivior Group's financial guidance including operating and profit margins for 2024 and its medium- and long-term growth outlook; assumptions regarding expected changes in market share and expectations regarding the extent and impact of competition; assumptions regarding future exchange rates; strategic priorities, s ...

Indivior PLC (NASDAQ:INDV) Q4 2023 Earnings Conference Call February 22, 2024 8:00 AM ET Company Participants Jason Thompson - VP, IR Mark Crossley - CEO Christian Heidbreder - Chief Scientific Officer Ryan Preblick - CFO Conference Call Participants Thibault Boutherin - Morgan Stanley Max Herrmann - Stifel Operator Good day, and thank you for standing by. Welcome to the Indivior 2023 Full Year Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentatio ...

February 22, 2024 Strong Underlying Financial Performance and Execution Against Strategic Priorities in 2023 Comment by Mark Crossley, CEO of Indivior PLC "At our December 2022 Capital Markets Day, we laid out Indivior's strategy and medium term financial goals targeting double-digit top line growth, operating margin expansion and strengthened cash flow. By executing against our strategic priorities, we delivered strongly against these goals in 2023. We grew SUBLOCADE and PERSERIS® net revenue by 54% and 50 ...

Indivior PLC (INVVY) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Mark Crossley - CEO Ryan Preblick - CFO Dr. Christian Heidbreder - Chief Scientific Officer Jason Thompson - VP, IR Conference Call Participants James Vane-Tempest - Jefferies Thibault Boutherin - Morgan Stanley Max Herrmann - Stifel Jason Thompson Thanks, Sandra, and good morning, everyone, and welcome to our call to discuss our third quarter results. Before we begin, I need to remind you that today's com ...

• INDV 2000 (OUD3): Phase 1 study MAD6 LSLV in Q3-2023, Successful endof-Phase 1 meeting with FDA in Q4- 20235 • INDV 4002 (AUD3): Phase 2 data Q4- 20235 Q3 2023 financial highlights Key Takeaways (vs. Q3 2022) ➤ Reported SG&A expenses driven by litigation provision; Adjusted SG&A expenses up 33% reflecting increased legal costs, Opiant and OPVEE launch expenses, SUBLOCADE commercial investments and cost inflation 2 See reconciliation pages in the appendix 3 Actual FX (foreign exchange) rates Cash & Borrowi ...